Current Opinion in Molecular Therapeutics

2.8(top 10%)

impact factor

887(top 20%)

papers

12.9K(top 20%)

citations

44(top 20%)

h-index

2.9(top 20%)

impact factor

923

all documents

13.1K

doc citations

59(top 20%)

g-index

Top Articles

#	Title	Journal	Year	Citations
1	Adeno-associated virus vector integration	Current Opinion in Molecular Therapeutics	2009	117
2	Peptoids as potential therapeutics	Current Opinion in Molecular Therapeutics	2009	104
3	Shotgun proteomics: tools for the analysis of complex biological systems	Current Opinion in Molecular Therapeutics	2002	96
4	MicroRNAs: biogenesis, function and applications	Current Opinion in Molecular Therapeutics	2009	94
5	AS-1411, a guanosine-rich oligonucleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia	Current Opinion in Molecular Therapeutics	2010	90
6	BiTE: Teaching antibodies to engage T-cells for cancer therapy	Current Opinion in Molecular Therapeutics	2009	88
7	Personalized medicine	Current Opinion in Molecular Therapeutics	2002	85
8	Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview	Current Opinion in Molecular Therapeutics	2009	79
9	Novel functions for small RNA molecules	Current Opinion in Molecular Therapeutics	2009	72
10	CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease	Current Opinion in Molecular Therapeutics	2010	72
11	BC-819, a plasmid comprising the H19 gene regulatory sequences and diphtheria toxin A, for the potential targeted therapy of cancers	Current Opinion in Molecular Therapeutics	2010	71
12	Immunogenicity of therapeutic monoclonal antibodies	Current Opinion in Molecular Therapeutics	2003	68
13	Off-targeting and other non-specific effects of RNAi experiments in mammalian cells	Current Opinion in Molecular Therapeutics	2007	67
14	Virus combinations and chemotherapy for the treatment of human cancers	Current Opinion in Molecular Therapeutics	2008	67
15	NMR-based metabolomics: translational application and treatment of cancer	Current Opinion in Molecular Therapeutics	2007	66
16	Adipose-derived stem and stromal cells for cell-based therapy: current status of preclinical studies and clinical trials	Current Opinion in Molecular Therapeutics	2010	66
17	Transcriptional gene silencing through epigenetic changes mediated by non-coding RNAs	Current Opinion in Molecular Therapeutics	2010	65
18	High-capacity 'gutless' adenoviral vectors	Current Opinion in Molecular Therapeutics	2001	65
19	Adipose-derived mesenchymal cells as a potential cell source for skeletal regeneration	Current Opinion in Molecular Therapeutics	2005	65
20	Subcutaneous administration of biotherapeutics: current experience in animal models	Current Opinion in Molecular Therapeutics	2010	65
21	Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans	Current Opinion in Molecular Therapeutics	2004	64
22	Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders	Current Opinion in Molecular Therapeutics	2009	64
23	mRNA-based gene transfer as a tool for gene and cell therapy	Current Opinion in Molecular Therapeutics	2007	61
24	Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss	Current Opinion in Molecular Therapeutics	2010	60
25	Overview of phase I studies of intravenous administration of PV701, an oncolytic virus	Current Opinion in Molecular Therapeutics	2003	59
26	The therapeutic potential of antisense-mediated exon skipping	Current Opinion in Molecular Therapeutics	2008	59
27	RNAi therapeutics: an update on delivery	Current Opinion in Molecular Therapeutics	2008	59
28	Tanezumab, a recombinant humanized mAb against nerve growth factor for the treatment of acute and chronic pain	Current Opinion in Molecular Therapeutics	2010	58
29	The use of neural stem cells in cancer gene therapy: predicting the path to the clinic	Current Opinion in Molecular Therapeutics	2010	57
30	Enhancing vaccines with immune stimulatory CpG DNA	Current Opinion in Molecular Therapeutics	2001	56
31	Metabonomics: systems biology in pharmaceutical research and development	Current Opinion in Molecular Therapeutics	2004	56
32	Clinical trials in neurological disorders using AAV vectors: promises and challenges	Current Opinion in Molecular Therapeutics	2004	54
33	Shotgun proteomics: integrating technologies to answer biological questions	Current Opinion in Molecular Therapeutics	2003	53
34	Immunoliposomes for cancer therapy	Current Opinion in Molecular Therapeutics	2006	50
35	Newcastle disease virus as a vaccine vector for humans	Current Opinion in Molecular Therapeutics	2008	50
36	NT-501: an ophthalmic implant of polymer-encapsulated ciliary neurotrophic factor-producing cells	Current Opinion in Molecular Therapeutics	2008	50
37	Malaria vaccines: are we getting closer?	Current Opinion in Molecular Therapeutics	2007	49
38	Evading the immune response upon in vivo gene therapy with viral vectors	Current Opinion in Molecular Therapeutics	2009	47
39	Striking out at disseminated metastases: the systemic delivery of oncolytic viruses	Current Opinion in Molecular Therapeutics	2006	47
40	Drug evaluation: the C5a receptor antagonist PMX-53	Current Opinion in Molecular Therapeutics	2006	47
41	Antivector and antitransgene host responses in gene therapy	Current Opinion in Molecular Therapeutics	2000	46
42	The host response to cancer virotherapy	Current Opinion in Molecular Therapeutics	2008	46
43	Cancer therapy with bispecific antibodies: Clinical experience	Current Opinion in Molecular Therapeutics	2010	45
44	Polyethylenimines for in vivo gene delivery	Current Opinion in Molecular Therapeutics	2001	45
45	Improving DNA vaccine potency via modification of professional antigen presenting cells	Current Opinion in Molecular Therapeutics	2003	45
46	Prime-boost immunization strategies for infectious diseases	Current Opinion in Molecular Therapeutics	2002	44
47	Proteomics approaches towards antigen discovery and vaccine development	Current Opinion in Molecular Therapeutics	2002	44
48	Reslizumab, a humanized anti-IL-5 mAb for the treatment of eosinophil-mediated inflammatory conditions	Current Opinion in Molecular Therapeutics	2009	44
49	Cytokine- and chemokine-based gene therapy for cancer	Current Opinion in Molecular Therapeutics	2003	43
50	Small interfering RNA for experimental cancer therapy	Current Opinion in Molecular Therapeutics	2005	43

Scientometrics

Overviews

Citing Bodies

Current Opinion in Molecular Therapeutics

Top Articles